Prestige Consumer Healthcare Publishes Inaugural Sustainability Report
06 Juillet 2023 - 10:30PM
Prestige Consumer Healthcare Inc. (the “Company” or “Prestige”)
(NYSE: PBH) today announced the release of its inaugural
Environmental, Social, and Corporate Governance (ESG)
Sustainability Report. The report highlights the Company’s ESG
attributes and the steps it has taken to establish baselines to
measure the Company’s sustainability strategy. The Company’s ESG
framework is centered on three pillars – supporting an inclusive
workforce, responsible corporate citizenship, and producing
sustainably.
To read the full Prestige Consumer Healthcare 2023
Sustainability Report and learn more about the Company’s ESG
journey, please visit esg.prestigeconsumerhealthcare.com.
“We are a company dedicated to delivering our consumers a safe
and efficacious consumer healthcare product portfolio that is
supported by our Company’s Environmental, Social and Corporate
Governance framework,” said Ron Lombardi, Chief Executive Officer
of Prestige Consumer Healthcare. “That mission is the guiding force
behind our operations and we’re proud to formally share with all of
our stakeholders how it has helped to inform our ESG strategy. We
have internally aligned ourselves to identify where opportunities
exist in terms of addressing key ESG issues and have anchored ESG
into all facets of our business. By leveraging our guiding
principles, we pledge as a company to address each ESG topic to
ensure we continually help our consumers care for themselves and
their loved ones for generations to come.”
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare is a leading consumer healthcare
products company with sales throughout the U.S. and Canada,
Australia, and in certain other international markets. The
Company’s diverse and iconic portfolio of brands include Monistat®
and Summer’s Eve® women's health products, BC® and Goody's® pain
relievers, Clear Eyes® and TheraTears® eye care products, DenTek®
specialty oral care products, Dramamine® motion sickness
treatments, Fleet® enemas and glycerin suppositories, Chloraseptic®
and Luden's® sore throat treatments and drops, Compound W® wart
treatments, Little Remedies® pediatric over-the-counter products,
Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment,
Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte®
rehydration products and the Fess® line of nasal and sinus care
products in Australia. Visit the Company's website at
www.prestigeconsumerhealthcare.com.
Investor Relations Contact
Phil Terpolilli, CFA,
914-524-6819irinquiries@prestigebrands.com
Source: Prestige Consumer Healthcare Inc.
Prestige Consumer Health... (NYSE:PBH)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Prestige Consumer Health... (NYSE:PBH)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024